Sunday, November 8, 2026

USD/EUR Bearish Momentum With A 2% Drop In The Last 10 Sessions

ViaNews Editorial Team

November 15, 2023

USD/EUR Bearish Momentum With A 2% Drop In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.6% for the last 10 sessions. At 15:09 EST on Wednesday, 15 November, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 3.811% up from its 52-week low and 5.84% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.01%, a negative 0.08%, and a positive 0.29%, respectively.

USD/EUR's highest amplitude of average volatility was 0.21% (last week), 0.29% (last month), and 0.29% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy hovers around 151.70, US CPI data looms. According to FXStreet on Tuesday, 14 November, "The USD/JPY pair consolidates its recent losses during the Asian session on Tuesday. ", "This, in turn, might lift the US Dollar (USD) and act as a tailwind for the USD/JPY pair. "
  • Usd/jpy price analysis: moves on the upward trajectory toward 152.00 level. According to FXStreet on Monday, 13 November, "The USD/JPY pair eyes a potential ascent towardthe major resistance at the psychological level of 152.00. ", "Adding to the positive outlook, the Moving Average Convergence Divergence (MACD) line is situated above the centerline and the signal line in the USD/JPY pair. "
  • Usd/jpy technical analysis: cautious waiting for Japanese intervention - 13 November 2023. According to DailyForex on Monday, 13 November, "In the near term, and according to the performance on the hourly chart, it appears that the USD/JPY currency pair is trading within an ascending channel formation. ", "In the long term, and according to the performance on the daily chart, it also appears that the USD/JPY is trading within an upward channel. "
  • Forex today: usd/jpy reaches new 1-year high price - 13 November 2023. According to DailyForex on Monday, 13 November, "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});The US Dollar is strong, as it was at the end of last week, and this has boosted the USD/JPY currency pair to a new 1-year high price below ¥152. "
  • Usd/jpy recovers from sudden plunge, on Japanese authorities intervention threats. According to FXStreet on Monday, 13 November, "The USD/JPY paired some of its earlier losses after plunging 67 pips in the last hour to a daily low of 151.20 amid the lack of news and reiterating comments of Japanese authorities that FX moves are undesirable and reflect fundamentals. ", "Meanwhile, the USD/JPY plunged from around 151.88 daily high toward 151.20 at around 15:01 GMT, with the move halting at around 15:07 GMT at 151.20 as buyers entered the markets, lifting the exchange rate towards the current spot price."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com